10-K: Goodness Growth Holdings Grants Stock Options to Key Executives Amidst Financial Reporting

Goodness Growth Holdings has disclosed a non-statutory stock option agreement for Kyle Kingsley and a non-plan stock option agreement for Joshua Rosen, alongside its annual 10-K filing, detailing the terms of executive compensation.

Summary

• Goodness Growth Holdings has granted stock options to key executives, Kyle Kingsley and Joshua Rosen, as part of their compensation packages.
• Kyle Kingsley received 671,402 subordinate voting shares with an exercise price of $0.301, vesting over time until December 31, 2026, and expiring on December 14, 2032.
• Joshua Rosen received 2,000,000 subordinate voting shares with an exercise price of $0.30, vesting in tranches between December 14, 2022 and October 1, 2023, and expiring on December 14, 2032.
• The options are non-statutory, meaning they do not qualify for special tax treatment under the Internal Revenue Code.
• The document also outlines the terms of vesting, exercise, and what happens in the event of a change in control, termination, disability, or death of the optionee.
• The document also includes details about the company's 10-K filing, including a cautionary statement regarding forward-looking statements, a business overview, risk factors, and financial information.
• The company operates in Maryland, Minnesota, and New York, with 14 retail dispensaries and wholesale operations.
• The company is undergoing a transformation to be more customer-centric and is focused on achieving positive operating cash flow.
• The company is involved in litigation with Verano Holdings Inc. after a failed acquisition agreement.
• The company is subject to various risks, including federal illegality of cannabis, changing state regulations, and competition.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as revenue growth and strategic positioning, the company faces significant challenges including ongoing losses, litigation, and regulatory risks. The sentiment is therefore cautiously negative.

Positives

• The company is focused on achieving positive operating cash flow through cost discipline, operational excellence, and product quality.
• The company is strategically located in three limited-license medical and adult-use markets.
• The company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations.

Negatives

• The company is involved in litigation with Verano Holdings Inc. after a failed acquisition agreement.
• The company has a history of operating losses and negative cash flows.
• The company anticipates requiring additional financing to operate its business.
• The company faces intense competition in a new and rapidly growing industry.
• The company's internal controls over financial reporting may not be effective.

Risks

• Marijuana remains illegal under U.S. federal law, posing a risk of federal enforcement.
• U.S. state and local regulation of cannabis is uncertain and changing.
• The company is involved in litigation with Verano, the outcome of which is uncertain.
• Cannabis businesses have restricted access to banking and other financial services.
• The company operates in a highly regulated sector and may not always succeed in complying fully with applicable regulatory requirements.
• The company has a history of operating losses and its management has concluded that factors raise substantial doubt about its ability to continue as a going concern.
• The company anticipates requiring additional financing to operate its business and may face difficulties acquiring additional financing on terms acceptable to it, or at all.
• The company faces security risks related to its physical facilities and cash transfers due to the mostly cash nature of the cannabis industry.
• The company's intellectual property may be difficult to protect.
• The company faces intense competition in a new and rapidly growing industry from licensed companies with more experience and financial resources than it has and from unlicensed, unregulated participants.

Future Outlook

The company's principal business objectives over the next 12-month period include achieving positive operating cash flow through cost discipline, operational excellence, and product quality; improving the quality and efficiency of flower production in Maryland and Minnesota; pursuing non-core asset divestitures; managing the balance sheet with capital partners to grow into being a strong credit.

Management Comments

• Management believes the medical and adult-use cannabis industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the cannabis produced.
• Management believes that production at scale is critical to drive down unit cost.
• Management believes that products with consistent quality can demand higher retail prices.

Industry Context

The cannabis industry is highly competitive with many operators, including large multi-state operators and smaller regional and local enterprises. The company faces competition from other companies that have greater resources, enhanced access to public equity and debt markets, superior cultivation and manufacturing capabilities, lower operating costs, better-located retail facilities, more experienced management, or that may be more mature as businesses.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards, but it does mention that the company faces competition from other companies with greater resources and experience.
• The document notes that the industry is highly competitive with many operators, including large multi-state operators and smaller regional and local enterprises.
• The document also mentions that pricing pressure for dried flower in several mature cannabis markets has led some operators to eschew cultivation, while the transition from medical-only to adult-use cannabis has increased wholesale market prices significantly in certain markets.

Legal Proceedings

• The company is involved in litigation with Verano Holdings Inc. after a failed acquisition agreement.
• The company was involved in litigation with Dr. Mark Schneyer, which was settled in April 2023.

Related Party Transactions

• For the years ended December 31, 2023, and 2022, the Company paid a related party (Bengal Impact Partners, of which Joshua Rosen, who is the Companys Chief Executive Officer, Interim Chief Financial Officer, and a member of the Companys Board of Directors, is a managing partner) $1,613 and $120,000 , respectively, for ongoing corporate advisory services.

Stakeholder Impact

• Shareholders face the risk of losing their investment due to the company's financial challenges and the uncertainty of the litigation outcome.
• Employees may be affected by potential cost-cutting measures and restructuring efforts.
• Customers may experience changes in product availability and pricing as the company focuses on operational efficiency.
• Suppliers and creditors may be impacted by the company's financial instability and potential asset divestitures.

Next Steps

• The company plans to achieve positive operating cash flow through cost discipline, operational excellence, and product quality.
• The company plans to improve the quality and efficiency of flower production in Maryland and Minnesota.
• The company plans to pursue non-core asset divestitures.
• The company plans to manage the balance sheet with capital partners to grow into being a strong credit.

Key Dates

Keywords

cannabis, stock options, executive compensation, financial reporting, legal proceedings, regulation, risk factors, multi-state operator, retail dispensaries, wholesale, cultivation, manufacturing